Low muscle mass affect hip fracture treatment outcomes in older individuals: a single-institution case-control study.
Case–control studies
Hip fracture
Sarcopenia
Journal
BMC musculoskeletal disorders
ISSN: 1471-2474
Titre abrégé: BMC Musculoskelet Disord
Pays: England
ID NLM: 100968565
Informations de publication
Date de publication:
09 Mar 2021
09 Mar 2021
Historique:
received:
01
12
2020
accepted:
26
02
2021
entrez:
22
3
2021
pubmed:
23
3
2021
medline:
15
5
2021
Statut:
epublish
Résumé
Although sarcopenia has been known as a risk factor for hip fracture, only a few reports have described the impact of muscle mass on hip fracture treatment outcomes. The current study aimed to investigate the impact of muscle mass on hip fracture treatment outcomes. This case-control study involved 337 patients (67 males and 270 females) with hip fracture aged ≥65 years (mean age: 84.1 ± 7.1 years) who underwent orthopedic surgery from January 2013 to June 2019. The mean follow-up period was 17.1 (1-60) months. Upon admission, all patients were assessed for low muscle mass according to the Asian Working Group for Sarcopenia criteria (male, SMI < 7.00 kg/m The prevalence of low muscle mass in patients with hip fracture was 231(68.5%). Those with low muscle mass had a lower Barthel index (P < 0.0001), hospital discharge rate (P = 0.035) and higher one-year mortality (P = 0.010). Cox proportional hazards regression analysis adjusted for age and sex found that low muscle mass was a risk factor for one-year mortality (hazard ratio, 3.182, 95% confidence interval, 1.097-9.226, P = 0.033). Patients with hip fracture who had low muscle mass had a lower Barthel index, lower home discharge rate, and higher one-year mortality. Moreover, low muscle mass was identified as a risk factor for one-year mortality among those with hip fracture. The aforementioned findings may help clinicians better manage those with hip fracture.
Sections du résumé
BACKGROUND
BACKGROUND
Although sarcopenia has been known as a risk factor for hip fracture, only a few reports have described the impact of muscle mass on hip fracture treatment outcomes. The current study aimed to investigate the impact of muscle mass on hip fracture treatment outcomes.
METHODS
METHODS
This case-control study involved 337 patients (67 males and 270 females) with hip fracture aged ≥65 years (mean age: 84.1 ± 7.1 years) who underwent orthopedic surgery from January 2013 to June 2019. The mean follow-up period was 17.1 (1-60) months. Upon admission, all patients were assessed for low muscle mass according to the Asian Working Group for Sarcopenia criteria (male, SMI < 7.00 kg/m
RESULTS
RESULTS
The prevalence of low muscle mass in patients with hip fracture was 231(68.5%). Those with low muscle mass had a lower Barthel index (P < 0.0001), hospital discharge rate (P = 0.035) and higher one-year mortality (P = 0.010). Cox proportional hazards regression analysis adjusted for age and sex found that low muscle mass was a risk factor for one-year mortality (hazard ratio, 3.182, 95% confidence interval, 1.097-9.226, P = 0.033).
CONCLUSIONS
CONCLUSIONS
Patients with hip fracture who had low muscle mass had a lower Barthel index, lower home discharge rate, and higher one-year mortality. Moreover, low muscle mass was identified as a risk factor for one-year mortality among those with hip fracture. The aforementioned findings may help clinicians better manage those with hip fracture.
Identifiants
pubmed: 33750363
doi: 10.1186/s12891-021-04143-6
pii: 10.1186/s12891-021-04143-6
pmc: PMC7945055
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
259Références
J Formos Med Assoc. 2020 Dec;119(12):1807-1816
pubmed: 32107098
Clin Orthop Relat Res. 1998 Mar;(348):29-36
pubmed: 9553530
Geriatr Gerontol Int. 2015 Apr;15(4):443-8
pubmed: 25155100
Clin Rheumatol. 2004 Feb;23(1):6-10
pubmed: 14749973
Age Ageing. 2019 Jul 1;48(4):601
pubmed: 31081853
J Orthop Surg (Hong Kong). 2020 Jan-Apr;28(2):2309499020918422
pubmed: 32329390
Arch Gerontol Geriatr. 2012 Sep-Oct;55(2):e48-52
pubmed: 22647380
J Cachexia Sarcopenia Muscle. 2019 Jun;10(3):485-500
pubmed: 30993881
Geriatr Gerontol Int. 2014 Feb;14 Suppl 1:122-8
pubmed: 24450570
Br J Sports Med. 2015 Oct;49(19):1262-7
pubmed: 26238869
J Am Med Dir Assoc. 2020 Mar;21(3):300-307.e2
pubmed: 32033882
Geriatr Gerontol Int. 2013 Apr;13(2):413-20
pubmed: 22816427
Md State Med J. 1965 Feb;14:61-5
pubmed: 14258950
Clin Nutr. 2020 Jan;39(1):33-39
pubmed: 30665817
Mol Cell Biol. 2014 Feb;34(4):606-18
pubmed: 24298022
Am J Clin Nutr. 2005 Oct;82(4):777-83
pubmed: 16210706
JAMA Netw Open. 2020 Oct 1;3(10):e2020836
pubmed: 33074327
Osteoporos Int. 2004 Jan;15(1):38-42
pubmed: 14593451
J Gerontol A Biol Sci Med Sci. 2005 Feb;60(2):213-6
pubmed: 15814865
CMAJ. 2009 Sep 1;181(5):265-71
pubmed: 19654194
J Trauma Manag Outcomes. 2012 Feb 15;6(1):2
pubmed: 22333003
J Orthop Sci. 2006 Mar;11(2):127-34
pubmed: 16568383
Am J Clin Nutr. 2009 Dec;90(6):1579-85
pubmed: 19864405
J Am Med Dir Assoc. 2016 Aug 1;17(8):675-7
pubmed: 27470918
J Bone Metab. 2018 Nov;25(4):227-233
pubmed: 30574467
Geriatr Gerontol Int. 2016 Sep;16(9):1021-7
pubmed: 26338368
Eur Spine J. 2016 Nov;25(11):3424-3431
pubmed: 25690348
Acta Orthop. 2009 Jun;80(3):308-13
pubmed: 19593721
Clin Interv Aging. 2015 May 11;10:859-69
pubmed: 25999704
Eur J Cancer. 2016 Apr;57:58-67
pubmed: 26882087
J Nutr. 1997 May;127(5 Suppl):990S-991S
pubmed: 9164280
Osteoporos Int. 2004 Jul;15(7):567-74
pubmed: 14730422